Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT ID: NCT06660355

Last Updated: 2025-11-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-23
• Study Completion Date: 2028-12-31

Brief Summary

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting (after prednisone failure), Ruxolitinib represents an ideal agent to test in the primary therapy setting. Here investigators propose a phase 2 randomized study to compare Ruxolitinib to prednisone as a first-line therapy in the treatment of chronic GVHD.

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ruxolitinib Treatment Arm

Ruxolitinib is administered as 10 mg orally twice daily in 28-day cycles.

Group Type: EXPERIMENTAL

Ruxolitinib

Intervention Type: DRUG

Ruxolitinib is a Janus kinase inhibitor.

Prednisone Treatment Arm

Prednisone will be started at 1mg/kg/day based on patient current body weight in kilograms.

Group Type: ACTIVE_COMPARATOR

Prednisone

Intervention Type: DRUG

Prednisone is a glucocorticoid.

Interventions

Ruxolitinib

Ruxolitinib is a Janus kinase inhibitor.

Intervention Type: DRUG

Prednisone

Prednisone is a glucocorticoid.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years.
• Karnofsky performance status ≥60%.
• Patients with a diagnosis of chronic GVHD per NIH diagnostic criteria5 who are in need for first systemic therapy as per treating physician's discretion, Overlap chronic GVHD will be allowed.
• No new immune suppressive therapy added within preceding 2 weeks prior to study enrolment.
• Able to take oral medications.
• Participants must have adequate organ and marrow function as defined below:

1. absolute neutrophil count ≥1,000/mcL

2. platelets ≥30,000/mcL

3. Hemoglobin ≥ 7 g/dL

4. Bilirubin ≤ 3 times institutional upper limit of normal (ULN) unless attributable to GVH

d. AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN unless attributable to GVH e. creatinine clearance ≥30 ml/min

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Previously treated with systemic immune suppressive therapy for chronic GVHD (where the indication for start of that systemic immune suppressive therapy was chronic GVHD).
• Patients with clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction, or stroke within 6 months, New York Heart Association class III or IV heart failure will be excluded.
• Relapse malignancy post- transplant.
• Active hepatitis B, hepatitis C and HIV will be excluded.
• Any uncontrolled infection at the time if enrollment will be excluded.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ruxolitinib.
• Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women and lactating women are excluded from this study because of the potential for teratogenic or abortifacient effects and an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Ruxolitinib, breastfeeding should be discontinued if the mother is treated with Ruxolitinib.
• Current or history of active Tuberculosis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Incyte Corporation

INDUSTRY

Sponsor Role: collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Farhad Khimani, MD

Role: PRINCIPAL_INVESTIGATOR

Moffitt Cancer Center

Locations

Moffitt Cancer Center

Tampa, Florida, United States

Site Status: RECRUITING

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Sarah Starr

Role: CONTACT

Phone: 813-745-2690

Email: Sarah.Starr@moffitt.org

Other Identifiers

MCC-23051

Identifier Type: -

Identifier Source: org_study_id